BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 19036624)

  • 1. The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions.
    Girard J
    Diabetes Metab; 2008 Dec; 34(6 Pt 1):550-9. PubMed ID: 19036624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes.
    Gautier JF; Choukem SP; Girard J
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S65-72. PubMed ID: 18640588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin hormones: Their role in health and disease.
    Nauck MA; Meier JJ
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New physiological effects of the incretin hormones GLP-1 and GIP.
    Asmar M
    Dan Med Bull; 2011 Feb; 58(2):B4248. PubMed ID: 21299928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 and control of insulin secretion.
    Thorens B
    Diabete Metab; 1995 Dec; 21(5):311-8. PubMed ID: 8586147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The concept of incretins and the physiological roles of incretins].
    Kawamori R
    Nihon Rinsho; 2011 May; 69(5):761-9. PubMed ID: 21595259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
    Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
    Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RD Lawrence Lecture 2017 Incretins: the intelligent hormones in diabetes.
    Gault VA
    Diabet Med; 2018 Jan; 35(1):33-40. PubMed ID: 29044772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin hormones and type 2 diabetes.
    Nauck MA; Müller TD
    Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
    Hansotia T; Drucker DJ
    Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.
    Ranganath LR
    J Clin Pathol; 2008 Apr; 61(4):401-9. PubMed ID: 18375745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.
    Pederson RA; Satkunarajah M; McIntosh CH; Scrocchi LA; Flamez D; Schuit F; Drucker DJ; Wheeler MB
    Diabetes; 1998 Jul; 47(7):1046-52. PubMed ID: 9648827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
    Finan B; Ma T; Ottaway N; Müller TD; Habegger KM; Heppner KM; Kirchner H; Holland J; Hembree J; Raver C; Lockie SH; Smiley DL; Gelfanov V; Yang B; Hofmann S; Bruemmer D; Drucker DJ; Pfluger PT; Perez-Tilve D; Gidda J; Vignati L; Zhang L; Hauptman JB; Lau M; Brecheisen M; Uhles S; Riboulet W; Hainaut E; Sebokova E; Conde-Knape K; Konkar A; DiMarchi RD; Tschöp MH
    Sci Transl Med; 2013 Oct; 5(209):209ra151. PubMed ID: 24174327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
    Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
    Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Incretin and bone].
    Yamada Y
    Clin Calcium; 2009 Sep; 19(9):1312-7. PubMed ID: 19721203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?
    Holst JJ
    BioDrugs; 2002; 16(3):175-81. PubMed ID: 12102645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.